gdc
Prostate Cancer

When Should Men Begin (and Stop) Prostate Cancer Screening?

Frank dela Rama explains the current recommendations for screening for prostate cancer.
Video Library – March 6, 2019
Frank dela Rama, RN, MS, AOCNS
Clinical Nurse Specialist, Oncology/Genomics
CANCER CARE Palo Alto Medical Foundation
Palo Alto, CA
Frank dela Rama explains the current recommendations for screening for prostate cancer.

Share this:

Recommended For You
FDA Approvals, News & UpdatesProstate Cancer
Orgovyx First FDA-Approved Oral Hormone Therapy for Patients with Advanced Prostate Cancer
In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic.
Prostate Cancer
Drugs for Prostate Cancer
Here are the drugs and financial support services available to patients receiving treatment for Prostate Cancer.
Prostate Cancer
Lynparza Improves Quality of Life in Men with Metastatic Prostate Cancer
By Meg Barbor, MPH
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
Prostate Cancer
The Combination of Cabometyx plus Tecentriq Improves Outcomes in Patients with Advanced Prostate Cancer
By Meg Barbor, MPH
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Last modified: March 19, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country